top of page

FDA Grants RMAT to Kamau's Sickle Cell Therapy That Corrects the Mutation Itself

4 hours ago
3 min read

On November 12, 2026, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to nula-cel, Kamau Therapeutics' gene-corrected stem cell therapy for sickle cell disease. Unlike the approved sickle cell gene therapies, nula-cel is designed to correct the sickle mutation itself, turning the faulty hemoglobin gene back into the normal one.

Early data from the RESTORE trial show that all three patients treated with Kamau's optimized manufacturing process are free of transfusions and have had no pain crises.


Illustration of red blood cells in a vessel, some sickle-shaped and some round, with a DNA strand being corrected in the background

The patients this is for

Sickle cell disease is caused by a single-letter change in the HBB gene, which makes part of hemoglobin, the protein that carries oxygen in red blood cells. The changed hemoglobin, called HbS, sticks together and bends red blood cells into a stiff, sickle shape. These cells block blood flow and cause sudden, severe pain called vaso-occlusive events (VOEs), as well as organ damage and a shorter life. About 100,000 people in the US live with sickle cell disease.


How nula-cel works

Doctors collect a patient's own blood-forming stem cells. In the lab, a CRISPR-Cas9 cut is made at the sickle mutation, and a DNA template with the correct sequence is supplied so that the cell's own repair system copies the correct letter into the gene. This approach is called homology-directed repair. After chemotherapy clears space in the bone marrow, the corrected cells are infused back, where they can make red blood cells with normal adult hemoglobin.

The two approved gene therapies work differently. Casgevy uses CRISPR to switch fetal hemoglobin back on, and Lyfgenia adds a modified hemoglobin gene with a viral vector. Beam's base-editing therapy, which recently met its pivotal goal, also raises fetal hemoglobin.


Diagram showing stem cells collected from a patient, CRISPR-Cas9 correcting the HBB gene with a DNA template, and corrected cells making healthy red blood cells

The early results

RESTORE (NCT04819841) is a Phase 1/2 trial planned to enroll about 15 patients aged 12 to 40 with severe sickle cell disease.

  • All 3 patients treated with the optimized process are transfusion-independent and have had no VOEs.

  • The 2 patients followed for more than six months have HbS below 20%, with most of their hemoglobin being normal adult hemoglobin.

Nula-cel also has Fast Track and Orphan Drug designations. Kamau expects to share more data later in 2026.


What RMAT means

RMAT designation is for cell and gene therapies that treat serious conditions and show early clinical promise. It gives developers more frequent FDA meetings and makes them eligible for priority review and accelerated approval. It is not an approval and does not mean the therapy has been proven to work.


The bottom line

The FDA's RMAT designation puts nula-cel, a therapy that directly repairs the sickle cell mutation in a patient's own stem cells, on a faster development track. The first three patients on the optimized process are transfusion-free with no pain crises, but larger numbers and longer follow-up are needed.



Keep exploring with Gene Tech Times

As an Amazon Associate, Gene Tech Times earns from qualifying purchases.

— T.N., Gene Tech Times

Comments


Subscribe for News

bottom of page